LONG COVID · LOW-DOSE NALTREXONE · CLINICAL PHARMACOLOGY
Low-Dose Naltrexone in Long COVID: Navigating Paradoxical Responses, Dose Sensitivity, and the Case for Ultra-Low-Dose Initiation A clinical commentary on individualized titration, interpreting worsening symptoms, and the emerging science of LDN in post-acute sequelae of SARS-CoV-2 Yoon Hang Kim MD MPH | Board Certified in